Table of Contents

company-logo

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Myriad Genetics Dividend Announcement

• Myriad Genetics announced a semi annually dividend of $1.75 per ordinary share which will be made payable on . Ex dividend date: 2009-07-01
• Myriad Genetics's trailing twelve-month (TTM) dividend yield is -%

Myriad Genetics Dividend History

Ex-Div dateDividend amountDividend typePay date
2009-07-01$1.75semi annually
2009-06-15$1.75semi annually

Myriad Genetics Dividend per year

Myriad Genetics Dividend Yield

Myriad Genetics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Myriad Genetics stock? Use our calculator to estimate your expected dividend yield:

Myriad Genetics Financial Ratios

P/E ratio-11.66
PEG ratio0.47
P/B ratio1.85
ROE-15.39%
Payout ratio0.00%
Current ratio1.90
Quick ratio1.73
Cash Ratio0.65

Myriad Genetics Dividend FAQ

Does Myriad Genetics stock pay dividends?
Myriad Genetics does not currently pay dividends to its shareholders.
Has Myriad Genetics ever paid a dividend?
No, Myriad Genetics has no a history of paying dividends to its shareholders. Myriad Genetics is not known for its dividend payments.
Why doesn't Myriad Genetics pay dividends?
There are several potential reasons why Myriad Genetics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Myriad Genetics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Myriad Genetics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Myriad Genetics a dividend aristocrat?
Myriad Genetics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Myriad Genetics a dividend king?
Myriad Genetics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Myriad Genetics a dividend stock?
No, Myriad Genetics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Myriad Genetics stocks?
To buy Myriad Genetics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Myriad Genetics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.